List of Excipients in Branded Drug NURTEC ODT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	NURTEC ODT	rimegepant sulfate	72618-3000	BENZYL ALCOHOL	2033-02-25
Pfizer Laboratories Div Pfizer Inc	NURTEC ODT	rimegepant sulfate	72618-3000	EUCALYPTOL	2033-02-25
Pfizer Laboratories Div Pfizer Inc	NURTEC ODT	rimegepant sulfate	72618-3000	LIMONENE	2033-02-25
Pfizer Laboratories Div Pfizer Inc	NURTEC ODT	rimegepant sulfate	72618-3000	MANNITOL	2033-02-25

Nurtec ODT Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: October 14, 2026

Nurtec ODT is Pfizer’s orally disintegrating rimegepant product for acute and preventive treatment of migraine. Its commercial position depends on three linked assets: rapid oral disintegration without water, a tolerable taste profile, and patent protection around rimegepant formulations and use. The excipient platform creates opportunities for generic design-around products, improved pediatric and geriatric formulations, alternate manufacturing technologies, and differentiated migraine delivery systems.

Nurtec ODT is not a biologic and does not face biosimilar competition. Potential competitors must use the abbreviated new drug application pathway and address listed patents through Paragraph IV certification, a section viii statement, or a later launch after patent expiry.

What is Nurtec ODT and how does its formulation work?

Nurtec ODT contains 75 mg of rimegepant, a small-molecule calcitonin gene-related peptide receptor antagonist. The tablet is designed to disintegrate on the tongue without water and is swallowed after dispersion.

The FDA-approved inactive ingredients include:

Excipient or component	Likely formulation function
Mannitol	Water-soluble diluent, cooling mouthfeel, tablet bulk
Microcrystalline cellulose	Structural filler and compression aid
Crospovidone	Superdisintegrant that accelerates tablet breakup
Sodium stearyl fumarate	Lubricant for tableting
Sucralose	High-intensity sweetener
Flavoring	Taste masking and patient acceptability
Colloidal silicon dioxide	Flow aid and processing support

The exact commercial value of the formulation is not limited to the ingredient list. ODT performance depends on particle size, compression force, porosity, moisture control, flavor system, packaging, and the interaction between rimegepant and the excipients.

Why mannitol is commercially important

Mannitol is widely used in ODT products because it provides a relatively clean mouthfeel and dissolves rapidly. It can produce a cooling sensation that supports patient acceptance, but excessive mannitol content can create friability, capping, or moisture-management problems.

A generic manufacturer can use alternative polyols or blends, including lactose, sorbitol, xylitol, or co-processed excipient systems. Those substitutions may avoid formulation claims but can alter sweetness, hygroscopicity, tablet strength, and disintegration time.

Why crospovidone matters

Crospovidone is the principal rapid-disintegration tool in the formulation. Its performance depends on grade, particle morphology, loading level, and compression conditions. Substitution with croscarmellose sodium, sodium starch glycolate, or a proprietary co-processed disintegrant may create a design-around product.

The commercial challenge is balancing fast disintegration against mechanical strength. An ODT that disintegrates rapidly but breaks during packaging, shipping, or handling is unlikely to match the reference product commercially.

Why taste masking is a major barrier

Rimegepant and its salt form can create an unacceptable bitter or medicinal taste. Sucralose and flavoring address sensory acceptance, but commercial equivalence requires more than matching the sweetener. A generic product may need a different flavor system, polymeric taste masker, ion-exchange resin, coated drug particle, or microencapsulated active ingredient.

Taste masking is an important opportunity for excipient suppliers and contract development and manufacturing organizations because a successful alternative can improve patient acceptance without reproducing the branded formulation.

What FDA approvals and exclusivity protect Nurtec ODT?

The FDA approved Nurtec ODT in February 2020 for the acute treatment of migraine in adults with or without aura. In May 2021, the FDA approved it for preventive treatment of episodic migraine in adults. The preventive indication expanded the commercial market and increased the value of method-of-use protection.[1]

Milestone	Date
Original FDA approval for acute migraine	February 27, 2020
Preventive migraine approval	May 2021
Active ingredient	Rimegepant sulfate
Dosage form	75 mg orally disintegrating tablet
Regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable

The original new chemical entity exclusivity period generally protected the product from submission of an ANDA for five years from the initial approval date, subject to statutory exceptions. That period ended in February 2025. Patent protection, pediatric exclusivity, regulatory stays, and litigation remain separate from FDA exclusivity.

What patents protect Nurtec ODT?

Nurtec ODT is protected by a portfolio rather than a single patent. The relevant patent categories include:

1. Composition-of-matter patents covering rimegepant or related CGRP receptor antagonist compounds.
2. Solid-state, salt, crystal-form, and pharmaceutical composition patents.
3. Formulation patents covering orally disintegrating tablets and excipient systems.
4. Method-of-use patents covering acute migraine treatment.
5. Method-of-use patents covering migraine prevention.
6. Manufacturing and process patents covering the active ingredient or finished dosage form.

The core composition patents typically provide the strongest protection because a competing rimegepant product cannot avoid them through an excipient substitution. Formulation patents are more vulnerable to design-around strategies, particularly where claims require specific excipients, concentration ranges, dissolution profiles, or manufacturing parameters.

The FDA Orange Book should be used for the current patent listing, expiry dates, pediatric extensions, and any applicable regulatory exclusivity. Orange Book entries can change through patent-listing updates, delisting requests, litigation outcomes, and corrections.[2]

How strong is the Nurtec ODT patent estate?

The estate is stronger against an identical rimegepant product than against a therapeutically equivalent ODT using a different formulation architecture.

Protection layer	Generic vulnerability	Commercial significance
Rimegepant composition claims	Low if valid and enforceable	Can block the active ingredient itself
Salt or crystal-form claims	Medium	May permit alternative solid forms
ODT formulation claims	Medium to high	Excipients and process parameters may be changed
Taste-masking claims	Medium	Alternative flavor and coating technologies are available
Acute-treatment claims	Medium	Section viii strategies may be possible
Preventive-treatment claims	Medium	Label carve-outs may be contested
Manufacturing claims	Variable	Depends on process overlap and detectability

The strongest commercial defense is a combination of valid active-ingredient claims, formulation claims, and method-of-use claims. No single excipient is likely to determine generic entry.

When does Nurtec ODT lose exclusivity?

The practical generic-entry date depends on the latest enforceable patent that covers the proposed ANDA product, not merely the end of NCE exclusivity.

An ANDA applicant may certify that listed patents are invalid, unenforceable, or not infringed under Paragraph IV. If the patent holder sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to court action and statutory exceptions.[3]

A generic applicant can also use a section viii statement to omit a patented indication from its labeling. For Nurtec ODT, that strategy could involve an acute-migraine label without the preventive indication, depending on the scope and enforceability of the listed method-of-use patents.

What generic launch scenarios exist?

Scenario	Description	Likely commercial result
No Paragraph IV filing	Generic waits for patent barriers to fall	Delayed but lower litigation cost
Paragraph IV challenge	Applicant contests validity or infringement	Earlier potential approval, high litigation exposure
Section viii carve-out	Generic omits a patented use	Partial market entry
Formulation design-around	Alternative ODT excipients or process	Avoids some formulation claims
Non-ODT rimegepant product	Tablet, capsule, or other oral dosage form	May compete on price but not fully match Nurtec
Authorized generic	Originator-approved or licensed generic	Faster substitution and price pressure

What formulation patents and excipient opportunities matter most?

Commercial opportunities cluster around technologies that reproduce Nurtec ODT’s patient experience without copying its formulation claims.

Co-processed ODT excipients

Co-processed systems can combine a filler, binder, and disintegrant in a single engineered material. They may improve flow, compressibility, and disintegration while reducing the number of conventional excipients. Suppliers with proprietary co-processed mannitol-cellulose or mannitol-disintegrant platforms may compete for generic rimegepant development programs.

Taste-masking systems

Potential technologies include:

• Polymer-coated rimegepant particles
• Ion-exchange resin complexes
• Lipid-based taste barriers
• Cyclodextrin complexes
• Microencapsulation
• pH-modified flavor systems
• Alternative high-intensity sweetener blends

The most valuable approach is one that preserves rapid drug release after swallowing while reducing bitterness during oral residence.

Moisture-resistant packaging

ODTs are sensitive to humidity and mechanical stress. Aluminum-aluminum blister packs, high-barrier films, desiccant systems, and optimized thermoforming can reduce tablet degradation. Packaging suppliers may capture value even where the excipient composition differs only modestly from the reference product.

Pediatric and geriatric formats

Rimegepant products for younger patients, older adults, or patients with dysphagia could use smaller tablets, modified flavors, lower-strength units, or multiparticulate systems. These products would require FDA approval and supporting safety, dosing, and bioavailability data. The commercial opportunity is greater if the product solves a use problem that the standard 75 mg ODT does not address.

Which companies are challenging Nurtec ODT?

The FDA does not provide a complete public database of all confidential ANDA applicants or every Paragraph IV notice. Publicly identifiable litigation should be checked through PACER, district court dockets, FDA Paragraph IV records where available, and the current Orange Book.

The competitive field includes:

• Generic pharmaceutical companies with established ODT capabilities
• Specialty generic companies focused on migraine and central nervous system products
• Contract development and manufacturing organizations with direct-compression and taste-masking platforms
• Excipient suppliers with co-processed disintegrants and rapid-dissolution technologies
• Innovators developing oral CGRP antagonists or alternate delivery systems

A company does not need to reproduce Nurtec ODT exactly to compete. A lower-cost conventional rimegepant tablet, an alternate acute-migraine product, or a preventive migraine therapy could take share through payer substitution.

What is the Orange Book status of Nurtec ODT?

Nurtec ODT is listed in the FDA Orange Book under its approved rimegepant product and NDA. The Orange Book is the controlling source for listed patents and exclusivity data, but it does not determine whether a patent is valid, infringed, or enforceable.

Key Orange Book review points include:

• NDA number 212728
• Listed patent numbers and expiration dates
• Pediatric exclusivity, if applicable
• Use codes for acute and preventive migraine treatment
• Whether patents cover the active ingredient, dosage form, or method of use
• Whether an ANDA applicant can use a section viii carve-out

The patent list should be reviewed immediately before any investment, licensing, or litigation decision because listed patents and legal outcomes can change.

What is the commercial opportunity around Nurtec ODT excipients?

The largest opportunity is not a single commodity excipient. It is an integrated platform that delivers:

1. Rapid tablet disintegration.
2. Acceptable taste.
3. Adequate hardness and low friability.
4. Stable performance under humidity exposure.
5. Scalable direct compression or low-complexity manufacturing.
6. A defensible design-around position.

Excipient vendors can monetize this opportunity through development partnerships, formulation licenses, technical-service agreements, and supply contracts. CDMOs can offer end-to-end rimegepant development, including taste masking, analytical method development, blister packaging, and comparative dissolution testing.

The most defensible commercial position is a proprietary excipient or process package that is difficult to substitute and supported by regulatory precedent. Commodity mannitol or crospovidone alone has limited strategic value because multiple qualified suppliers exist.

How does Nurtec ODT compare with competing migraine products?

Product	Active ingredient	Dosage form	Main differentiation	Competitive pressure
Nurtec ODT	Rimegepant	ODT	Acute and preventive use without water	Generic rimegepant and CGRP competition
Ubrelvy	Ubrogepant	Conventional tablet	Acute migraine treatment	Same therapeutic class
Qulipta	Atogepant	Conventional tablet	Preventive migraine treatment	Preventive oral CGRP competition
Reyvow	Lasmiditan	Conventional tablet	Non-CGRP mechanism	Different safety and driving restrictions
Triptans	Various	Tablets, ODTs, nasal and injectable forms	Low-cost established class	Strong payer and generic pressure

Nurtec ODT’s excipient and dosage-form advantage is strongest in patients who value portability, water-free administration, and a single product for acute and preventive treatment. Its price premium is more exposed where payers favor low-cost triptans or generic alternatives.

What revenue exposure does Pfizer face from generic entry?

Pfizer acquired Biohaven’s commercial CGRP portfolio in 2022. Nurtec ODT and Vydura are the same rimegepant product marketed under different regional names. Pfizer reports product revenue in its annual and quarterly filings, but reported figures can combine regional brands and may be affected by rebates, foreign exchange, channel inventory, and collaboration accounting.[4]

Generic entry would likely affect revenue in stages:

• Initial authorized-generic or limited-entry competition could reduce net price.
• Multiple ANDA approvals could produce rapid payer-driven substitution.
• A section viii launch could initially target only acute or preventive use.
• Non-ODT rimegepant products could create price pressure without full dosage-form substitution.
• ODT-specific advantages may preserve some branded share after generic entry.

The highest exposure is in price-sensitive formularies where therapeutic substitution is easy. The lowest exposure is in patients who specifically value water-free administration or have difficulty swallowing conventional tablets.

Key Takeaways

• Nurtec ODT uses a conventional but commercially optimized ODT excipient platform centered on mannitol, microcrystalline cellulose, crospovidone, sodium stearyl fumarate, sucralose, flavoring, and colloidal silicon dioxide.
• Taste masking, tablet robustness, moisture control, and rapid disintegration are the main technical barriers.
• The patent estate includes active-ingredient, formulation, method-of-use, and manufacturing protection.
• NCE exclusivity ended in February 2025, but patent protection may continue to delay generic approval.
• Generic applicants can pursue Paragraph IV challenges, section viii carve-outs, formulation design-arounds, or non-ODT rimegepant products.
• Excipient suppliers have the greatest opportunity in integrated ODT platforms rather than commodity ingredients.
• Nurtec ODT is not subject to biosimilar competition because rimegepant is a small molecule.
• The FDA Orange Book and current court dockets are the controlling sources for live patent and litigation analysis.
• Generic entry would pressure both price and market share, with the greatest exposure in payer-controlled channels.

FAQs

Can a generic use the same excipients as Nurtec ODT?

Yes, unless the specific excipient combination or formulation is covered by an enforceable patent claim. Using the same excipients does not by itself establish infringement, but the complete formulation and manufacturing process must be evaluated.

Can a generic rimegepant product omit the preventive migraine indication?

Potentially. An ANDA applicant may pursue a section viii carve-out if the preventive indication is protected by a listed method-of-use patent and the proposed labeling omits the patented use.

Is mannitol necessary for a rimegepant orally disintegrating tablet?

No. Mannitol is commercially useful but not necessarily mandatory. Alternative fillers or co-processed excipient systems may provide acceptable disintegration and mouthfeel.

What is the most difficult Nurtec ODT attribute to reproduce?

Taste acceptance is often the most difficult attribute because it depends on the active ingredient, particle size, residence time in the mouth, sweetener, flavor, coating, and disintegration behavior.

Could a conventional rimegepant tablet compete with Nurtec ODT?

Yes. A conventional tablet could compete on price and active ingredient, but it may not match Nurtec ODT’s water-free administration, patient experience, or branded recognition.

References

1. U.S. Food and Drug Administration. (2020). FDA approves new treatment for adults with migraine. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
4. Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://www.pfizer.com/investors/financial-information/sec-filings